Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Evan Wu
Metastatic Thymic Mucoepidermoid Carcinoma: The Diagnostic Challenges and Role of CRTC1/MAML2 Translocation in Accurate Diagnosis and Treatment
1 Introduction Mucoepidermoid carcinoma (MEC) was first identified in 1945 [1], as a histological subtype of salivary gland tumors, characterized as an epithelial neoplasm originating from the submucosa and is histologically characterized by the presence of squamous cells, mucin-secreting goblet cells, and intermediate cells. While initially discovered in the salivary glands, this histological pattern has also been identified in the thymus.
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.
FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
Biomarker Testing in Non-Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Immunotherapy Efficacy Prediction in Cancer: An Artificial Intelligence Approach with Unannotated H&E Whole-Slide Images
The authors have declared no competing interest. This study did not receive any funding I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The analysis presented in the manuscript uses data from patients that provided informed consent including for secondary reuse.
Conserved spatiotemporal expression landscape of dominant tRNA genes in human and mouse
Abstract Transfer RNAs are integral for protein synthesis and the interpretation of the information contained in DNA. To date, a few methods, including custom microarrays and custom targeted sequencing, have been used to quantify tRNA. However, methods using available RNA-sequencing data have not yet been reported.
Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Key Points Question Is tumor histological grade associated with immunotherapy response in patients with recurrent or metastatic mucosal head and neck squamous cell carcinoma? Findings In this cohort study of 60 patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitors, patients with high-grade tumors were more likely to have a clinically beneficial response to immunotherapy than patients with low-grade tumors.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Evan
Contact Evan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack